 Michael Leibowitz
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 6 | 2013 | 527 | 0.870 |
Why?
| | Carcinoma, Squamous Cell | 5 | 2013 | 626 | 0.820 |
Why?
| | Hamartoma Syndrome, Multiple | 1 | 2022 | 14 | 0.780 |
Why?
| | Hemangiosarcoma | 1 | 2022 | 20 | 0.770 |
Why?
| | STAT1 Transcription Factor | 2 | 2013 | 69 | 0.760 |
Why?
| | Neuroblastoma | 1 | 2022 | 152 | 0.720 |
Why?
| | Skin Neoplasms | 1 | 2022 | 829 | 0.460 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2013 | 166 | 0.440 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2013 | 21 | 0.420 |
Why?
| | Tumor Escape | 2 | 2019 | 38 | 0.390 |
Why?
| | HLA Antigens | 1 | 2013 | 236 | 0.370 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2011 | 128 | 0.340 |
Why?
| | Immunotherapy | 2 | 2009 | 584 | 0.270 |
Why?
| | Interleukin-6 | 1 | 2008 | 716 | 0.230 |
Why?
| | Antigen Presentation | 3 | 2011 | 205 | 0.220 |
Why?
| | Cancer Vaccines | 3 | 2009 | 164 | 0.200 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2019 | 833 | 0.180 |
Why?
| | PTEN Phosphohydrolase | 1 | 2022 | 148 | 0.180 |
Why?
| | NAD | 1 | 2020 | 71 | 0.170 |
Why?
| | Endomyocardial Fibrosis | 1 | 2019 | 3 | 0.170 |
Why?
| | RNA, Small Interfering | 2 | 2013 | 577 | 0.160 |
Why?
| | Metabolomics | 1 | 2024 | 594 | 0.160 |
Why?
| | Genomics | 1 | 2024 | 716 | 0.160 |
Why?
| | Ovarian Neoplasms | 1 | 2024 | 484 | 0.160 |
Why?
| | Lactic Acid | 1 | 2020 | 296 | 0.160 |
Why?
| | Interleukin-12 | 1 | 2019 | 118 | 0.150 |
Why?
| | Calcineurin | 1 | 2019 | 90 | 0.150 |
Why?
| | Cell Line, Tumor | 4 | 2019 | 3114 | 0.150 |
Why?
| | Proteomics | 1 | 2024 | 988 | 0.150 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 74 | 0.150 |
Why?
| | STAT3 Transcription Factor | 2 | 2011 | 187 | 0.150 |
Why?
| | Fibroblasts | 2 | 2019 | 946 | 0.140 |
Why?
| | Biomarkers | 1 | 2008 | 3878 | 0.140 |
Why?
| | Transforming Growth Factor beta | 1 | 2019 | 460 | 0.130 |
Why?
| | Fibrosis | 1 | 2019 | 518 | 0.130 |
Why?
| | Carcinoma | 2 | 2011 | 214 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 288 | 0.130 |
Why?
| | Peptides | 3 | 2009 | 904 | 0.120 |
Why?
| | Cytokines | 3 | 2019 | 1997 | 0.100 |
Why?
| | Interferon-gamma | 2 | 2013 | 759 | 0.100 |
Why?
| | Cell Differentiation | 1 | 2019 | 1858 | 0.090 |
Why?
| | Keratinocytes | 1 | 2013 | 240 | 0.090 |
Why?
| | Neoplasms, Squamous Cell | 1 | 2011 | 4 | 0.090 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2011 | 132 | 0.090 |
Why?
| | Immunoprecipitation | 1 | 2011 | 160 | 0.090 |
Why?
| | Down-Regulation | 1 | 2013 | 639 | 0.090 |
Why?
| | Immunoblotting | 1 | 2011 | 302 | 0.090 |
Why?
| | Humans | 14 | 2024 | 129079 | 0.080 |
Why?
| | T-Lymphocytes | 2 | 2008 | 1913 | 0.080 |
Why?
| | Receptor, EphA2 | 1 | 2008 | 19 | 0.080 |
Why?
| | Phosphorylation | 1 | 2013 | 1686 | 0.080 |
Why?
| | Antigen-Presenting Cells | 1 | 2008 | 151 | 0.070 |
Why?
| | Oligonucleotides | 1 | 2008 | 140 | 0.070 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2008 | 185 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1318 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1195 | 0.060 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 428 | 0.060 |
Why?
| | Pleural Effusion, Malignant | 1 | 2005 | 8 | 0.060 |
Why?
| | Telomerase | 1 | 2007 | 229 | 0.060 |
Why?
| | Recurrence | 1 | 2008 | 1013 | 0.060 |
Why?
| | Mesothelioma | 1 | 2005 | 38 | 0.060 |
Why?
| | Cell Survival | 1 | 2008 | 1085 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2007 | 510 | 0.050 |
Why?
| | Gene Expression | 1 | 2008 | 1477 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 267 | 0.050 |
Why?
| | Child | 1 | 2022 | 20860 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2005 | 377 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2008 | 996 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 596 | 0.040 |
Why?
| | Models, Biological | 1 | 2008 | 1704 | 0.040 |
Why?
| | Computational Biology | 1 | 2024 | 588 | 0.040 |
Why?
| | Antigens, Surface | 1 | 2019 | 151 | 0.040 |
Why?
| | Ovalbumin | 1 | 2019 | 179 | 0.040 |
Why?
| | Vaccination | 1 | 2007 | 1351 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 5282 | 0.040 |
Why?
| | Transcriptome | 1 | 2024 | 875 | 0.040 |
Why?
| | Antibodies, Neoplasm | 2 | 2008 | 35 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2019 | 162 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2019 | 1044 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 315 | 0.040 |
Why?
| | Breast Neoplasms | 2 | 2007 | 2116 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1174 | 0.040 |
Why?
| | Myofibroblasts | 1 | 2019 | 132 | 0.040 |
Why?
| | Bleomycin | 1 | 2019 | 241 | 0.040 |
Why?
| | Signal Transduction | 1 | 2011 | 4867 | 0.030 |
Why?
| | Animals | 5 | 2019 | 34708 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1014 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2009 | 10256 | 0.030 |
Why?
| | Collagen | 1 | 2019 | 433 | 0.030 |
Why?
| | Wound Healing | 1 | 2019 | 310 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 2043 | 0.030 |
Why?
| | Mice | 3 | 2019 | 16583 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1094 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2019 | 2082 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2020 | 2344 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1361 | 0.020 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2019 | 619 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2607 | 0.020 |
Why?
| | Female | 5 | 2024 | 68274 | 0.020 |
Why?
| | Vaccines, DNA | 1 | 2009 | 29 | 0.020 |
Why?
| | Receptors, Growth Factor | 1 | 2009 | 55 | 0.020 |
Why?
| | No-Observed-Adverse-Effect Level | 1 | 2008 | 6 | 0.020 |
Why?
| | bcl-X Protein | 1 | 2008 | 41 | 0.020 |
Why?
| | Macaca fascicularis | 1 | 2008 | 52 | 0.020 |
Why?
| | Toxicity Tests | 1 | 2008 | 30 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2008 | 63 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2008 | 255 | 0.020 |
Why?
| | Injections, Intramuscular | 1 | 2008 | 127 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2008 | 217 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2008 | 145 | 0.020 |
Why?
| | Mice, SCID | 1 | 2008 | 340 | 0.020 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2007 | 17 | 0.020 |
Why?
| | Interleukin-5 | 1 | 2007 | 38 | 0.020 |
Why?
| | Tubulin | 1 | 2008 | 131 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2009 | 227 | 0.020 |
Why?
| | HLA-DQ Antigens | 1 | 2007 | 180 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 2007 | 156 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2007 | 226 | 0.020 |
Why?
| | Th2 Cells | 1 | 2007 | 169 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2008 | 608 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 835 | 0.020 |
Why?
| | Lung | 1 | 2019 | 3925 | 0.020 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2007 | 203 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2009 | 478 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 65 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2007 | 543 | 0.010 |
Why?
| | CD4 Antigens | 1 | 2005 | 137 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 642 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 2050 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2846 | 0.010 |
Why?
| | Male | 3 | 2019 | 63248 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 3999 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 1061 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2005 | 2357 | 0.010 |
Why?
| | Aged | 1 | 2007 | 22068 | 0.000 |
Why?
| | Middle Aged | 1 | 2007 | 31024 | 0.000 |
Why?
| | Adult | 1 | 2007 | 35423 | 0.000 |
Why?
|
|
Leibowitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|